tetano
Editor, Senior Moderator
Eur J Neurol. 2017 Dec 4. doi: 10.1111/ene.13537. [Epub ahead of print]
[h=1]Antibody response to seasonal influenza vaccination in multiple sclerosis patients receiving immunomodulatory therapy.[/h] Olberg HK[SUP]1,[/SUP][SUP]2[/SUP], Eide GE[SUP]3,[/SUP][SUP]4[/SUP], Cox RJ[SUP]5,[/SUP][SUP]6,[/SUP][SUP]7[/SUP], Jul-Larsen ?[SUP]6,[/SUP][SUP]7[/SUP], Lartey SL[SUP]5,[/SUP][SUP]6,[/SUP][SUP]7[/SUP], Vedeler CA[SUP]1,[/SUP][SUP]2,[/SUP][SUP]8[/SUP], Myhr KM[SUP]9,[/SUP][SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] We have previously shown that multiple sclerosis patients receiving immunomodulatory treatment have reduced seroprotection rates after influenza immunization.
[h=4]OBJECTIVES:[/h] To further investigate the influence of immunomodulatory therapies on the antibody response and seroprotection rates in patients immunized with seasonal influenza vaccine in 2012/2013 compared to healthy controls.
[h=4]METHODS:[/h] Ninety patients receiving fingolimod, glatiramer acetate, interferon beta-1a/1b, natalizumab or no therapy were compared to 62 healthy controls. All subjects received the inactivated split virus vaccine in 2012 and serum samples were collected pre- and three, six and 12 months post-vaccination. The vaccine responses were evaluated by the haemagglutination inhibition assay and adjusted for age and gender.
[h=4]RESULTS:[/h] No significant differences in rates of protection against H1N1 for interferon beta-1a/1b and glatiramer acetate were observed as compared to controls at three, six and 12 months. Fingolimod provided reduced protection at all time points post-vaccination while natalizumab displayed reduced protection at three and six months. Patients without immunomodulation did not display significantly different protection rates as the controls at three and 12 months.
[h=4]CONCLUSION:[/h] These findings suggest that MS patients receiving fingolimod or natalizumab should be considered for a second dose of the vaccine in cases of insufficient protection. Our results further indicate that new immunomodulatory treatment regimens should be systematically evaluated for their influence on influenza-specific vaccine responses. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] Immunomodulation; Immunotherapy; Protection; multiple sclerosis; seasonal influenza vaccination
PMID: 29205701 DOI: 10.1111/ene.13537
[h=1]Antibody response to seasonal influenza vaccination in multiple sclerosis patients receiving immunomodulatory therapy.[/h] Olberg HK[SUP]1,[/SUP][SUP]2[/SUP], Eide GE[SUP]3,[/SUP][SUP]4[/SUP], Cox RJ[SUP]5,[/SUP][SUP]6,[/SUP][SUP]7[/SUP], Jul-Larsen ?[SUP]6,[/SUP][SUP]7[/SUP], Lartey SL[SUP]5,[/SUP][SUP]6,[/SUP][SUP]7[/SUP], Vedeler CA[SUP]1,[/SUP][SUP]2,[/SUP][SUP]8[/SUP], Myhr KM[SUP]9,[/SUP][SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] We have previously shown that multiple sclerosis patients receiving immunomodulatory treatment have reduced seroprotection rates after influenza immunization.
[h=4]OBJECTIVES:[/h] To further investigate the influence of immunomodulatory therapies on the antibody response and seroprotection rates in patients immunized with seasonal influenza vaccine in 2012/2013 compared to healthy controls.
[h=4]METHODS:[/h] Ninety patients receiving fingolimod, glatiramer acetate, interferon beta-1a/1b, natalizumab or no therapy were compared to 62 healthy controls. All subjects received the inactivated split virus vaccine in 2012 and serum samples were collected pre- and three, six and 12 months post-vaccination. The vaccine responses were evaluated by the haemagglutination inhibition assay and adjusted for age and gender.
[h=4]RESULTS:[/h] No significant differences in rates of protection against H1N1 for interferon beta-1a/1b and glatiramer acetate were observed as compared to controls at three, six and 12 months. Fingolimod provided reduced protection at all time points post-vaccination while natalizumab displayed reduced protection at three and six months. Patients without immunomodulation did not display significantly different protection rates as the controls at three and 12 months.
[h=4]CONCLUSION:[/h] These findings suggest that MS patients receiving fingolimod or natalizumab should be considered for a second dose of the vaccine in cases of insufficient protection. Our results further indicate that new immunomodulatory treatment regimens should be systematically evaluated for their influence on influenza-specific vaccine responses. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] Immunomodulation; Immunotherapy; Protection; multiple sclerosis; seasonal influenza vaccination
PMID: 29205701 DOI: 10.1111/ene.13537